Ignacio J Amat-Santos
Latest contributions
TAVI: LIVE Educational Case from Cleveland Clinic - London, UK
22 May 2026 – From EuroPCR 2026
This educational session from the Cleveland Clinic focuses on transcatheter aortic valve implantation (TAVI) in patients with significant landing zone calcification. It presents a detailed operator strategy and live case demonstrating the optimal use of a third generation intra-annular self-expanding valve, alongside approaches to coronary artery...
Real world practice inspiring new evidence generation in structural heart
21 May 2026 – From EuroPCR 2026
This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...
Imaging evaluation in structural heart interventions
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive evaluation of imaging techniques applied in structural heart interventions. It covers innovative studies including the impact of Dapagliflozin on multivalvular disease post-TAVI, advanced fusion methods combining CT and echocardiography to assess aortic stenosis severity, and the clinical relevance of the fibrocalcific...
Advancing TAVI practice
21 May 2026 – From EuroPCR 2026
Advancing TAVI practice is the focus of this session, addressing antiplatelet therapy choices, novel transcatheter treatments for pure aortic regurgitation, early hemodynamic valve deterioration as a prognostic marker, prosthesis-patient mismatch in redo-TAVI, pioneering valve-in-mechanical valve interventions, and comprehensive core-lab evaluation of implantation depth and clinical outcomes.
Beyond the horizon - Future of structural heart innovations and PCI
20 May 2026 – From EuroPCR 2026
Structural heart and coronary interventions are expanding rapidly, with innovation increasingly focused on managing complex anatomies and diversifying treatment strategies.
The PRISM-PCI toolkit is introduced as a framework to support decision-making in complex PCI, alongside advances in transcatheter valve therapies spanning mitral, tricuspid and pulmonary interventions, as...
Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection
20 May 2026 – From EuroPCR 2026
This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.
Unconventional situations during cardiovascular interventions
20 May 2026 – From EuroPCR 2026
This session addresses unconventional and challenging scenarios encountered during cardiovascular interventions, focusing on managing complications effectively in the cathlab. Through detailed case presentations from Argentina, Chile, and Colombia, it explores innovative approaches to acute aortic valve regurgitation, TAVI complications in bicuspid anatomy, and diagnostic dilemmas in...
Managing life-threatening TAVI complications
19 May 2026 – From EuroPCR 2026
Manage life-threatening complications in TAVI procedures with a structured algorithm for identification and resolution. This session shares expert tips for handling specific severe complications and reviews best practices aimed at complication avoidance to enhance patient safety and procedural success.
TAVI in women
22 May 2025 – From EuroPCR 2025
Focus on gender-specific considerations in TAVI with this session. Topics include timely management and referral disparities in women with severe aortic stenosis, early outcomes from the LANDMARK trial with latest-generation valves, insights from NAVULTRA comparing valve types, prosthesis-patient mismatch data, and gender differences in right ventricular...
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.
LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial
15 May 2024 – From EuroPCR 2024
This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography...
